Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing
Predictive Oncology (NASDAQ: POAI) has secured a $10 million Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global's investment fund. The agreement provides flexible funding access to advance the company's AI-driven drug discovery and repurposing initiatives.
Under the SEPA terms, POAI maintains full control over the timing and amount of stock sales, with no warrants, derivatives, or minimum commitments required. The funding will support ongoing drug discovery, biomarker research, and business development opportunities with biopharmaceutical companies through their AI and machine learning capabilities.
Predictive Oncology (NASDAQ: POAI) ha ottenuto un Accordo di Acquisto Azionario Standby (SEPA) da 10 milioni di dollari con il fondo di investimento di Yorkville Advisors Global. L'accordo offre accesso flessibile ai finanziamenti per far avanzare le iniziative dell'azienda nel campo della scoperta e riutilizzo di farmaci basati sull'intelligenza artificiale.
Secondo i termini del SEPA, POAI mantiene il pieno controllo sul momento e sull'entit脿 delle vendite azionarie, senza warrants, derivati o impegni minimi richiesti. I fondi supporteranno la continua scoperta di farmaci, la ricerca di biomarcatori e le opportunit脿 di sviluppo commerciale con aziende biofarmaceutiche, sfruttando le capacit脿 di AI e machine learning.
Predictive Oncology (NASDAQ: POAI) ha asegurado un Acuerdo de Compra de Acciones en Espera (SEPA) por 10 millones de d贸lares con el fondo de inversi贸n de Yorkville Advisors Global. El acuerdo proporciona acceso flexible a financiamiento para avanzar en las iniciativas de descubrimiento y reutilizaci贸n de medicamentos impulsadas por IA de la compa帽铆a.
Bajo los t茅rminos del SEPA, POAI mantiene el control total sobre el momento y la cantidad de ventas de acciones, sin warrants, derivados ni compromisos m铆nimos requeridos. El financiamiento apoyar谩 la investigaci贸n continua de medicamentos, el estudio de biomarcadores y las oportunidades de desarrollo comercial con compa帽铆as biofarmac茅uticas mediante sus capacidades de IA y aprendizaje autom谩tico.
Predictive Oncology (NASDAQ: POAI)電� Yorkville Advisors Global 韴瀽 韼�霌滌檧 1,000毵� 雼煬 攴滊鞚� 鞀ろ儬氚旍澊 欤检嫕 毵れ瀰 瓿勳暯(SEPA)鞚� 觳搓舶頄堨姷雼堧嫟. 鞚� 瓿勳暯鞚� 須岇偓鞚� AI 旮半皹 鞁犾暯 臧滊皽 氚� 鞛櫆鞖� 頂勲鞝濏姼毳� 歆勴枆頃� 靾� 鞛堧弰搿� 鞙犾棸頃� 鞛愱笀 臁半嫭 鞝戧芳鞚� 鞝滉车頃╇媹雼�.
SEPA 臁瓣贝鞐� 霐半澕 POAI電� 欤检嫕 毵り皝 鞁滉赴鞕� 攴滊鞐� 雽�頃� 鞝勳爜鞚� 韱奠牅甓�鞚� 鞙犾頃橂┌, 鞗岆煱韸�, 韺岇儩靸來拡 霕愲姅 斓滌唽 鞎届爼鞚� 頃勳殧頃橃 鞎婌姷雼堧嫟. 鞚措矆 鞛愱笀鞚� AI 氚� 毹胳嫚霟嫕 鞐焿鞚� 頇滌毄頃� 鞁犾暯 臧滊皽, 氚旍澊鞓る旎� 鞐瓣惮, 氚旍澊鞓れ牅鞎� 旮办梾瓿检潣 靷梾 臧滊皽 旮绊殞毳� 歆�鞗愴晿電� 雿� 靷毄霅� 鞓堨爼鞛呺媹雼�.
Predictive Oncology (NASDAQ : POAI) a conclu un accord d'achat d'actions en attente (SEPA) de 10 millions de dollars avec le fonds d'investissement de Yorkville Advisors Global. Cet accord offre un acc猫s flexible au financement pour faire progresser les initiatives de d茅couverte et de repositionnement de m茅dicaments bas茅es sur l'intelligence artificielle de la soci茅t茅.
Selon les termes du SEPA, POAI conserve un contr么le total sur le moment et le montant des ventes d'actions, sans n茅cessiter de bons de souscription, de d茅riv茅s ou d'engagements minimums. Ce financement soutiendra la d茅couverte continue de m茅dicaments, la recherche de biomarqueurs et les opportunit茅s de d茅veloppement commercial avec des entreprises biopharmaceutiques gr芒ce 脿 leurs capacit茅s en IA et apprentissage automatique.
Predictive Oncology (NASDAQ: POAI) hat eine Standby-Aktienkaufvereinbarung (SEPA) 眉ber 10 Millionen US-Dollar mit dem Investmentfonds von Yorkville Advisors Global abgeschlossen. Die Vereinbarung bietet flexiblen Zugang zu Finanzierung, um die KI-gest眉tzten Initiativen des Unternehmens zur Arzneimittelentdeckung und -neunutzung voranzutreiben.
Gem盲脽 den SEPA-Bedingungen beh盲lt POAI die volle Kontrolle 眉ber den Zeitpunkt und die H枚he der Aktienverk盲ufe, ohne dass Warrants, Derivate oder Mindestverpflichtungen erforderlich sind. Die Finanzierung wird die laufende Arzneimittelentdeckung, Biomarkerforschung und Gesch盲ftsentwicklung mit biopharmazeutischen Unternehmen durch deren KI- und Machine-Learning-F盲higkeiten unterst眉tzen.
- Secured access to up to $10 million in flexible funding
- Company maintains full control over timing and amount of stock sales
- No warrants, derivatives, or minimum commitments required
- No restrictions on company's operating activities
- Potential dilution of existing shareholders through new stock sales
- Agreement may result in downward pressure on stock price during sales
PITTSBURGH, July 08, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has entered into a standby equity purchase agreement (鈥淪EPA鈥�) with YA II PN, LTD, an investment fund managed by Yorkville Advisors Global, LP (鈥淵orkville鈥�). Predictive Oncology expects the partnership to provide an efficient and flexible source of funding, enabling the company to progress its ongoing drug discovery, biomarker discovery and drug repurposing initiatives, and business development opportunities with leading biopharmaceutical companies, leveraging its novel AI and machine learning capabilities.
Under the terms of the agreement, Predictive Oncology has the right to sell, and Yorkville has the obligation to purchase up to
A copy of the SEPA is available in the Company's Form 8-K that has been filed with the Securities and Exchange Commission.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these common shares in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company鈥檚 scientifically validated AI platform, PEDAL, is able to predict with
Investor Relations Contact:
Mike Moyer
LifeSci Advisors, LLC
Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward- looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥減lan,鈥� 鈥渨ould,鈥� 鈥渢arget鈥� and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading 鈥淩isk Factors鈥� in our filings with the SEC. Except as expressly required by law, the company disclaims any intent or obligation to update these forward-looking statements.
FAQ
What is the size of Predictive Oncology's (POAI) new equity purchase agreement with Yorkville?
How will POAI use the funds from the Yorkville agreement?
What are the key terms of POAI's Standby Equity Purchase Agreement?
Does the Yorkville agreement impose any restrictions on POAI's operations?
Is POAI required to use the full $10 million from the Yorkville agreement?
